Haematologica, Vol 92, Issue 8, 1127-1130 doi:10.3324/haematol.11288
Copyright © 2007 by Ferrata Storti Foundation
Fc
Emanuela Carlotti ,
Giuseppe A. Palumbo ,
Elena Oldani ,
Daniele Tibullo ,
Silvia Salmoiraghi ,
Andrea Rossi ,
Josee Golay ,
Alessandro Pulsoni ,
Robin Foà ,
Alessandro Rambaldi
We analyzed Fc
RIIIA-158V/F and FcRIIA-131H/R polymorphisms in a cohort of 94 newly diagnosed follicular lymphoma (FL) patients sequentially treated with CHOP and Rituximab. With a median follow-up of 5.8 years, the overall survival at 8 years is 83%. Univariate and multivariate analysis showed no correlation between FcRIIIA-158VV/VF and FcRIIA-131HH/HR polymorphisms and the overall response rate, the molecular response and the event-free survival obtained after CHOP and Rituximab. By contrast, the achievement of a durable molecular clearance of BCL2/IgH+ cells detectable in the bone marrow is confirmed to be a reliable predictive factor of a better long-term clinical outcome.
Patients
Ninety-four previously untreated patient from six different Italian centers were sequentially treated with 6 cycles of CHOP chemotherapy (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, and prednisone 100 mg/m2) and 4 weekly infusions of Rituximab. At diagnosis, 88 out of 94 patients proved positive for the rearrangement of the Bcl-2 proto-oncogene on chromosome 18 with the immunoglobulin heavy chain (IgH) region on chromosome 14 (BCL2/IgH). Among these patients, 68 had been previously enrolled in a published study designed to investigate whether the sequential infusion of CHOP and Rituximab could induce a durable eradication of Bcl2/IgH+ cells from the bone marrow (BM) or peripheral blood (PB).11 The study was conducted according to good clinical and laboratory practice rule and the principles of the Declaration of Helsinki. The local Ethics Review Committees approved the protocol at each center.
The correlation between FcRIIIA-158VV and FcRIIA-131HH genotypes and clinical response in FL after Rituximab immunotherapy is still controversial.6,7,9 We investigated 94 FL patients sequentially treated with CHOP and Rituximab to determine the influence of these two receptors on the clinical and molecular response and the long-term outcome. The distribution of genotypes in our cases was similar to that previously reported: 32% HH, 49% HR and 19% RR for FcRIIA and 19% VV, 49% VF and 32% FF for FcRIIIA. There was no significant difference in the distribution of FcRIIA and FcRIIIA polymorphisms and age, sex, B symptoms, LDH, bulky disease, number of extra-nodal sites, bone marrow infiltration and stage (data not shown). In our FL patients who received a sequential CHOP and Rituximab treatment, there was no difference in the overall response rate (complete and partial response) between patients with FcRIIIA-VV or FcRIIIA-VF/FF (95% vs. 88%, p=not significant, ns) and for patients with FcRIIA-HH or FcRIIA HR/RR (87% vs. 91%, p=ns). Furthermore, the rate of complete remission was similar irrespective of the different FcRs variants: 78% for FcRIIIA-VV, 70% for FcRIIIA-VF/FF (p=ns), 67% for FcRIIA-HH, and 73% for FcRIIA HR/RR (p=ns). Finally, no correlation was found between the FcRs genotypes and the achievement of molecular response (data not shown). Univariate and multivariate analysis at diagnosis showed positive predictive factors of clinical response after chemo-immunotherapy were the lack of bulky disease and normal LDH values. By contrast, the clinical stage, the involvement of extra-nodal sites (beyond BM), age, sex, B symptoms, BM infiltration, or the polymorphism of FcÁRIIIA–VV or the FcRIIA-RR were not statistically significant (Table 1). With a median follow-up of 5.8 years (range 1.18–9.04) the OS of these patients is 83% at 8 years (Figure 1A). This provides further evidence that the addition of Rituximab contributes to an increase in OS in FL patients.12–14 The EFS of patients with FcRIIIA-VV was 43% compared to 40% in patients bearing the combined FcRIIIA-VF/FF (p=ns) (Figure 1B). Similarly, the EFS of patients with FcRIIA-HH was 39% compared to 41% for patients with the FcRIIA-RR/HR (p=ns) (Figure 1C). By contrast, we confirm that the achievement of a durable BM clearance of BCL2/IgH+ cells detected by PCR analysis is associated with a better clinical outcome. Indeed, the long-term EFS of patients who proved PCR negative 1 year after the end of CHOP and Rituximab treatment remains significantly better compared to that of patients who never converted or rapidly lost a molecular response (52% vs. 24%, p=0.0009) (Figure 1D). The study showed FcRs variants did not influence prognosis. This may have been due to several factors. It may be related to the different clinical setting in which Rituximab was employed compared to previous studies: a positive correlation between FcRIIIA and FcRIIA polymorphisms had been previously reported when Rituximab was used as single agent, both in untreated FL patients6 or as a second or further line of treatment.7 Our results are in keeping with those reported by Boettcher and colleagues9 in a group of 75 FL patients treated with R-CHOP. In contrast to our results and those of Boettscher’s, Kim and co-workers reported a positive correlation between V/V carriers and response in DLBCL treated with R-CHOP.8 Apart from the different histology, these different results could perhaps be explained, at least in part, by the high proportion of V/V phenotype in the Asiatic population. In addition, the high remission rate obtained in our study may make it difficult to demonstrate differences in remission rate between V/V and F carrier patients, particularly if a large part of the therapeutic efficacy is due to chemotherapy. However, in contrast with this hypothesis, we previously showed that both CHOP and Rituximab can achieve a similar 2 log decrease of BCL2/IgH+ cells detectable in the bone marrow.15 As far as the FcRIIA is concerned, the lack of influence of the H/R polymorphism at position 131 is not surprising given the lack of effect of this amino acid on human IgG1 binding to this receptor.16 Thus, while FcRs variants are likely to play an important role when Rituximab is used alone, our results support the hypothesis that ADCC, and/or phagocytosis mediated by FcRIIIA and FcRIIA, may not be the most relevant mechanisms of action when this chimeric antibody is used in combination with chemotherapy. On the other hand, CHOP chemotherapy may also enhance ADCC/phagocytosis via other FcRs17 thus decreasing differences previously attributable to FcRIII polymorphisms. Indeed, different chemotherapy regimens do not reduce the number or function of circulating NK cells.18
To summarize, although FcRIIIA-158VV and FcRIIA-131HH genotypes are predictors of better clinical and molecular response in FL patients treated with Rituximab alone, this association seems to be lost when Rituximab is used in combination with or after chemotherapy.
the authors wish to thank Dr L. Arcaini (Divisione di Ematologia, IRCCS, Policlinico San Matteo Università di Pavia), Dr E. Morra (Divisione di Ematologia, Ospedale Niguarda Milano), Dr M. Rupolo (Oncologia Medica B e Nucleo di Ricerca Clinica e Laboratoristica in Ematologia, Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico, IRCCS, Aviano) and Dr F. Zaja (Chair of Hematology, Università di Udine) for updating the clinical data of patients referred to their centers. We thank also Dr J. Fitzgibbon for his critical review of the manuscript
Authors’ Contributions
Copyright © 2007 by Ferrata Storti Foundation
Malignant Lymphomas |
Fc
RIIIA and FcRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin’s lymphoma patients treated with sequential CHOP and rituximab
From the Divisione di Ematologia, Ospedali Riuniti Bergamo (EC, EO, SS, AR, JG, AR); CRUK Medical Oncology Laboratory, Barts and the London, Queen Mary School of Medicine and Dentistry, London, United Kingdom (EC); Dipartimento di Ematologia, Scienze Biomediche, Universita’, Catania (GAP, DT); Dipartimento di Biotecnologie Cellulari ed Ematologia, Università ‘La Sapienza’, Rome, Italy (AP, RF)
Correspondence: Alessandro Rambaldi, M.D., USC Hematology, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 24128 Bergamo, Italy. E-mail: arambaldi{at}ospedaliriuniti.bergamo.it
ABSTRACT
 TOP ABSTRACT Design and MethodsDiscussion and ResultsReferences |
|---|
We analyzed Fc
RIIIA-158V/F and FcRIIA-131H/R polymorphisms in a cohort of 94 newly diagnosed follicular lymphoma (FL) patients sequentially treated with CHOP and Rituximab. With a median follow-up of 5.8 years, the overall survival at 8 years is 83%. Univariate and multivariate analysis showed no correlation between FcRIIIA-158VV/VF and FcRIIA-131HH/HR polymorphisms and the overall response rate, the molecular response and the event-free survival obtained after CHOP and Rituximab. By contrast, the achievement of a durable molecular clearance of BCL2/IgH+ cells detectable in the bone marrow is confirmed to be a reliable predictive factor of a better long-term clinical outcome.
Key words: FcR polymorphisms, follicular lymphoma, BCL2/IgH rearrangements.
The chimeric anti-CD20 monoclonal antibody Rituximab is nowadays routinely used either as single agent or in combination with chemotherapy for the treatment of non-Hodgkin’s lymphomas (NHL). In particular, the addition of Rituximab to chemotherapy significantly improves the clinical outcome in previously untreated follicular lymphoma (FL) patients.1,2 The precise biological mechanism is still controversial, but several in vitro and in vivo studies have shown that Rituximab mediates its anti-lymphoma effect by complement-dependent cytotoxicity (CDC)3 antibody-dependent cellular cytotoxicity (ADCC)4 and, also possibly, through the induction of apoptosis.5 In ADCC, natural killer (NK) cells, neutrophils and macro-phages bind antibody-coated cells by receptors that recognize the constant region of immunoglobulin (Fc receptors, FcRs). A genomic polymorphism at amino acid 158 of FcRIIIA has been described whereby the presence of Valine (V) rather than Phenylalanine (F) leads to higher binding affinity to immunoglobulin G (IgG). A polymorphism at position 131 of FcRIIA has also been described (Histidine/Arginine, H/R). The FcRIIIA-VV and FcRIIA-HH genotypes have been associated with a better clinical and molecular response in FL patients treated as first line therapy with Rituximab alone6,7 and in patients with diffuse large B-cell lymphoma (DLBCL) treated with the concomitant administration of Rituximab and CHOP (R-CHOP).8 However, this is not the case in patients with FL treated with R-CHOP9 or in B-cell chronic lymphocytic leukemia (B-CLL) patients.10 We investigated the influence of FcRIIIA and FcRIIA polymorphisms in a cohort of 94 FL patients sequentially treated with CHOP and Rituximab in order to evaluate the effect of these polymorphisms on the clinical and molecular response to treatment, and on the overall outcome.
Design and Methods
|
TOPABSTRACTDesign and MethodsDiscussion and ResultsReferences |
|---|
Patients
Ninety-four previously untreated patient from six different Italian centers were sequentially treated with 6 cycles of CHOP chemotherapy (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, and prednisone 100 mg/m2) and 4 weekly infusions of Rituximab. At diagnosis, 88 out of 94 patients proved positive for the rearrangement of the Bcl-2 proto-oncogene on chromosome 18 with the immunoglobulin heavy chain (IgH) region on chromosome 14 (BCL2/IgH). Among these patients, 68 had been previously enrolled in a published study designed to investigate whether the sequential infusion of CHOP and Rituximab could induce a durable eradication of Bcl2/IgH+ cells from the bone marrow (BM) or peripheral blood (PB).11 The study was conducted according to good clinical and laboratory practice rule and the principles of the Declaration of Helsinki. The local Ethics Review Committees approved the protocol at each center.
Molecular analysis
A qualitative molecular evaluation of Bcl2/IgH+ cells was performed on 68/94 BM samples 1 year after the end of Rituximab administration as previously described.11 Genotyping of FcRIIIA and FcRIIA polymorphisms was performed on 94 BM or PB samples amplifying 100 ng of DNA on a Real-Time platform (LightCycler, Roche Molecular Biochemicals, Mannheim, Germany), in 20 µL with 1X LightCycler DNA Master Hybridization Probes buffer (Roche) for 50 cycles (1'' at 95°C, 5'' at 62°C, 7'' at 72°C) and subsequent melting. The 3' fluorescent labeled sensor probes and 5' RED 640 labeled anchor probes (TIB MOLBIOL, Genoa, Italy) employed were: 5'-GGAGAAACCATCATGCTGAG-3', 5'-CATACCTTGGACAGTGATGGTC-3', 5'-GTGGGATCCAAACGGGAGAA-3', 5'-TCTGGGATTTTCCATTCTGGAAGAATGTGACC-3' for FcRIIA and 5'-CATATTTACAGAATGGCAAAGGC-3', 5'-TGAGTGATGGTGATGTTCACAGT-3', 5'-CATTTTTACTCCCAAAAAGCCC-3', 5'-CTGCAGAAGTAGGAGCCGCTGT-3' for FcRIIIA. Melting curve analysis was performed by LightCycler 3.5 software. The genotype was confirmed by single base sequencing on an ABI Prism 310 Genetic Analyzer (Applera, Foster City, CA, USA), with the ABI Prism SNaPshot Multiplex Kit (Applera) according to the manufacturer’s instructions using 100 ng of genomic DNA and the sequencing primers 5'-GATGGAGAAGGTGGGATCCAAA-3' for FcRIIA and 5'-TTTTTTTTTCCTACTTCTGCAGGGGGCTT-3' for FcRIIIA.
Statistical analysis
Patients were analyzed for overall survival (OS) and for event-free survival (EFS) according to the Kaplan-Meier method. The log-rank test was used to analyze differences between curves. Univariate analysis was performed using a 
2 test and multivariate analysis by a multiple regression model. The following variables were evaluated: age, sex, serum LDH, bulky disease, BM infiltration, number of extra-nodal sites, FcRIIA (HH, HR, RR) and FcRIIIA (VV, VF, FF) genotypes.
Discussion and Results
|
TOPABSTRACTDesign and MethodsDiscussion and ResultsReferences |
|---|
The correlation between Fc
RIIIA-158VV and FcRIIA-131HH genotypes and clinical response in FL after Rituximab immunotherapy is still controversial.6,7,9 We investigated 94 FL patients sequentially treated with CHOP and Rituximab to determine the influence of these two receptors on the clinical and molecular response and the long-term outcome. The distribution of genotypes in our cases was similar to that previously reported: 32% HH, 49% HR and 19% RR for FcRIIA and 19% VV, 49% VF and 32% FF for FcRIIIA. There was no significant difference in the distribution of FcRIIA and FcRIIIA polymorphisms and age, sex, B symptoms, LDH, bulky disease, number of extra-nodal sites, bone marrow infiltration and stage (data not shown). In our FL patients who received a sequential CHOP and Rituximab treatment, there was no difference in the overall response rate (complete and partial response) between patients with FcRIIIA-VV or FcRIIIA-VF/FF (95% vs. 88%, p=not significant, ns) and for patients with FcRIIA-HH or FcRIIA HR/RR (87% vs. 91%, p=ns). Furthermore, the rate of complete remission was similar irrespective of the different FcRs variants: 78% for FcRIIIA-VV, 70% for FcRIIIA-VF/FF (p=ns), 67% for FcRIIA-HH, and 73% for FcRIIA HR/RR (p=ns). Finally, no correlation was found between the FcRs genotypes and the achievement of molecular response (data not shown). Univariate and multivariate analysis at diagnosis showed positive predictive factors of clinical response after chemo-immunotherapy were the lack of bulky disease and normal LDH values. By contrast, the clinical stage, the involvement of extra-nodal sites (beyond BM), age, sex, B symptoms, BM infiltration, or the polymorphism of FcÁRIIIA–VV or the FcRIIA-RR were not statistically significant (Table 1). With a median follow-up of 5.8 years (range 1.18–9.04) the OS of these patients is 83% at 8 years (Figure 1A). This provides further evidence that the addition of Rituximab contributes to an increase in OS in FL patients.12–14 The EFS of patients with FcRIIIA-VV was 43% compared to 40% in patients bearing the combined FcRIIIA-VF/FF (p=ns) (Figure 1B). Similarly, the EFS of patients with FcRIIA-HH was 39% compared to 41% for patients with the FcRIIA-RR/HR (p=ns) (Figure 1C). By contrast, we confirm that the achievement of a durable BM clearance of BCL2/IgH+ cells detected by PCR analysis is associated with a better clinical outcome. Indeed, the long-term EFS of patients who proved PCR negative 1 year after the end of CHOP and Rituximab treatment remains significantly better compared to that of patients who never converted or rapidly lost a molecular response (52% vs. 24%, p=0.0009) (Figure 1D). The study showed FcRs variants did not influence prognosis. This may have been due to several factors. It may be related to the different clinical setting in which Rituximab was employed compared to previous studies: a positive correlation between FcRIIIA and FcRIIA polymorphisms had been previously reported when Rituximab was used as single agent, both in untreated FL patients6 or as a second or further line of treatment.7 Our results are in keeping with those reported by Boettcher and colleagues9 in a group of 75 FL patients treated with R-CHOP. In contrast to our results and those of Boettscher’s, Kim and co-workers reported a positive correlation between V/V carriers and response in DLBCL treated with R-CHOP.8 Apart from the different histology, these different results could perhaps be explained, at least in part, by the high proportion of V/V phenotype in the Asiatic population. In addition, the high remission rate obtained in our study may make it difficult to demonstrate differences in remission rate between V/V and F carrier patients, particularly if a large part of the therapeutic efficacy is due to chemotherapy. However, in contrast with this hypothesis, we previously showed that both CHOP and Rituximab can achieve a similar 2 log decrease of BCL2/IgH+ cells detectable in the bone marrow.15 As far as the FcRIIA is concerned, the lack of influence of the H/R polymorphism at position 131 is not surprising given the lack of effect of this amino acid on human IgG1 binding to this receptor.16 Thus, while FcRs variants are likely to play an important role when Rituximab is used alone, our results support the hypothesis that ADCC, and/or phagocytosis mediated by FcRIIIA and FcRIIA, may not be the most relevant mechanisms of action when this chimeric antibody is used in combination with chemotherapy. On the other hand, CHOP chemotherapy may also enhance ADCC/phagocytosis via other FcRs17 thus decreasing differences previously attributable to FcRIII polymorphisms. Indeed, different chemotherapy regimens do not reduce the number or function of circulating NK cells.18 |
View this table: [in a new window] [Download PPT slide] |
Table 1. Predictive factors of clinical CR after sequential CHOP and Rituximab
|
 View larger version (13K): [in a new window] [Download PPT slide] |
Figure 1. Clinical outcome of 94 FL-NHL patients treated with sequential CHOP and Rituximab. OS of study patients (Panel A). EFS according to: FcRIIIA-VV genotype (Panel B), FcRIIA-HH genotype (Panel C) or the molecular evidence of BCL2/IgH+ cells detected in the BM 1 year after the end of treatment with Rituximab (Panel D). OS was calculated from the beginning of CHOP chemotherapy to the date of death or date of last follow-up. The EFS was calculated from the start of CHOP chemotherapy to the date of the first event (relapse, disease progression, treatment failure as defined by the need for any additional anti lymphoma treatment or death for any cause) or last follow-up.
|
RIIIA-158VV and FcRIIA-131HH genotypes are predictors of better clinical and molecular response in FL patients treated with Rituximab alone, this association seems to be lost when Rituximab is used in combination with or after chemotherapy.
Acknowledgments
the authors wish to thank Dr L. Arcaini (Divisione di Ematologia, IRCCS, Policlinico San Matteo Università di Pavia), Dr E. Morra (Divisione di Ematologia, Ospedale Niguarda Milano), Dr M. Rupolo (Oncologia Medica B e Nucleo di Ricerca Clinica e Laboratoristica in Ematologia, Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico, IRCCS, Aviano) and Dr F. Zaja (Chair of Hematology, Università di Udine) for updating the clinical data of patients referred to their centers. We thank also Dr J. Fitzgibbon for his critical review of the manuscript
Footnotes
Authors’ Contributions
EC, GAP, DT and SS performed the molecular analysis; AnR and AP followed the patients and provided blood and marrow samples; EO performed statistical analysis, JG and RF critically revised the manuscript; EC and AR planned the project, supervised the work and wrote the manuscript.
The authors reported no potential conflicts of interest.
Funding: this work was supported in part by grants from Associazione Italiana per la Ricerca contro il Cancro (AIRC), Consiglio Nazionale per le Ricerche (CNR) (Progetto Oncologia CU 03.00357), Ministero dell’Istruzione Università e Ricerca (MIUR), Associazione Paolo Belli and Associazione Italiana Lotta alla Leucemia (AIL), sezione Paolo Belli.
Received for publication January 19, 2007. Accepted for publication May 28, 2007.
References
|
TOPABSTRACTDesign and MethodsDiscussion and ResultsReferences |
|---|
- Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23.
[Abstract/Free Full Text] - Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32.
[Abstract/Free Full Text] - Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95:3900-8.
[Abstract/Free Full Text] - Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 2000;204:55-63.[CrossRef][Web of Science][Medline]
- Zhang N, Khawli LA, Hu P, Epstein AL. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin’s Lymphomas. Clin Cancer Res 2005;11:5971-80.
[Abstract/Free Full Text] - Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcRIIIa gene. Blood 2002;99:754-8.
[Abstract/Free Full Text] - Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
[Abstract/Free Full Text] - Kim DH, Jung HD, Kim JG, Lee J-J, Yang D-H, Park YH, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006;108:2720-5.
[Abstract/Free Full Text] - Boettcher S, Pott C, Ritgen M, Hiddemann W, Unterhalt M, Kneba M. Evidence for Fc{} receptor IIIA-independent rituximab Effector mechanisms in patients with follicular lymphoma treated with combined immuno-chemotherapy. ASH Annual Meeting Abstracts 2004;104:590-9.[Abstract]
- Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. Fc gamma RIIIa and FcRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004;103:1472-4.
[Abstract/Free Full Text] - Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002;99:856-62.
[Abstract/Free Full Text] - Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-52.
[Abstract/Free Full Text] - Marcus RE, Solal-Celigny P, Imrie K, Catalano JV, Dmoszynska A, Raposo JC, et al. MabThera (Rituximab) plus Cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin’s lymphoma (NHL). ASH Annual Meeting Abstracts 2006;108:481-8.
[Abstract/Free Full Text] - Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 2006;108:2540-4.
[Abstract/Free Full Text] - Rambaldi A, Carlotti E, Oldani E, Della Starza I, Baccarani M, Cortelazzo S, et al. Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood 2005;105:3428-33.
[Abstract/Free Full Text] - van der Pol WL, Jansen MD, Sluiter WJ, van de Sluis B, Leppers-van de Straat FG, Kobayashi T, et al. Evidence for non-random distribution of Fc receptor genotype combinations. Immunogenetics 2003;55:240-6.[CrossRef][Web of Science][Medline]
- Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004;199:1659-69.
[Abstract/Free Full Text] - Weng W-K, Czerwinski D, Levy R. Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood 2007;109:951-3.
[Abstract/Free Full Text]
This article has been cited by other articles:
 |
|
 |
|
  W.-K. Weng, R. S. Negrin, P. Lavori, and S. J. Horning Immunoglobulin G Fc Receptor Fc{gamma}RIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma J. Clin. Oncol., January 10, 2010; 28(2): 279 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Leidi, E. Gotti, L. Bologna, E. Miranda, M. Rimoldi, A. Sica, M. Roncalli, G. A. Palumbo, M. Introna, and J. Golay M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro J. Immunol., April 1, 2009; 182(7): 4415 - 4422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Pennell, T. Bhanji, L. Zhang, A. Seth, C. A. Sawka, and N. L. Berinstein Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma Haematologica, August 1, 2008; 93(8): 1265 - 1267. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||